All In Biotech

Drug Trial Radar · NCT02016560

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Sep 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

383

Actual

Start

Dec 2013

Primary completion

Jul 28, 2017

Study completion Jul 28, 2017

Sponsor

Lead sponsor
Avid RadiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 20, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).

Conditions

  • Alzheimer's Disease

Interventions

  • florbetapir F 18Drug

  • Flortaucipir F18Drug

  • Brain PET ScanProcedure

    positron emission tomography (PET) scan of the brain

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive DeclineTime frame: between baseline and 18 months
  2. Exploratory Phase: Cross-sectional Flortaucipir Imaging ResultsTime frame: baseline scan
  3. Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid StatusTime frame: baseline and 18 months

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Alzheimer's Institute

    Phoenix, Arizona

  • Four Peaks Neurology

    Scottsdale, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • UC Irvine

    Irvine, California

  • Hoag Memorial

    Newport Beach, California

  • Norther California PET Imaging Center

    Sacramento, California

  • UC Davis

    Sacramento, California

  • UC San Francisco

    San Francisco, California

  • Neurological Research Institute

    Santa Monica, California

  • Molecular NeuroImaging

    New Haven, Connecticut

  • Quantum Laboratories

    Deerfield Beach, Florida

  • 21st Century Oncology

    Fort Myers, Florida

  • Sandlake Imaging

    Orlando, Florida

  • Meridien Research

    St. Petersburg, Florida

  • USF Health Byrd Alzheimer's Center

    Tampa, Florida

  • Independent Imaging

    West Palm Beach, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston University

    Boston, Massachusetts

  • Alzheimer's Disease Center

    Quincy, Massachusetts

  • Center for Clinical Imaging Research

    St Louis, Missouri

  • Las Vegas Radiology

    Las Vegas, Nevada

  • Center for Brain Health - NYU Langone Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Butler Hospital

    Providence, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.